DNAPrint genomics Launches New Corporate Marketing and Product Branding Campaign Features Two Redesigned and Upgraded Web Sites SARASOTA, Fla., July 25 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC:DNAG) (BULLETIN BOARD: DNAG) today announced a new corporate marketing and product branding campaign focused on the Company's four distinct markets -- pharmacogenomics and test/drug combinations, forensics technology for law enforcement, consumer family heritage tests and genotyping services for pharmaceutical companies and universities. "We have made innovative changes in our corporate image and marketing approach, featuring new product and service logos and redesigned marketing materials for our key genetic products and services," stated President and Chief Executive Officer Richard Gabriel. "We have designed new packaging for our ANCESTRYbyDNA(TM) consumer product and for our DNAWitness(TM) forensics technology. In addition, we have activated two redesigned Web sites. One contains corporate information, product updates, newsletter membership and investor news ( http://www.dnaprint.com/ ). The second ( http://www.ancestrybydna.com/ ) targets the consumer market with product information and updates. We will launch a third Web site for our forensics products in the near future." This new campaign represents another major step in DNAPrint genomics' effort to market its products and services to a larger international market. "The DNAPrint genomics campaign has been one of the most exciting projects in the history of the agency," stated Peter Paul, President of the Inter Ad Agency of Sarasota. "We will continue work on the development of innovative product promotions using the visual corporate ID." About Inter Ad Agency Inter Ad Agency is an award-winning full-service advertising agency, providing national and international clients with creative development, marketing strategies and production for media ranging from print to broadcast, web development and public relations. Inter Ad Agency is located in Sarasota, FL. About DNAPrint genomics, Inc. DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in preclinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(TM), RETINOME (TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). Forward-Looking Statements All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Company Contact: Richard Gabriel CEO and President 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848 DATASOURCE: DNAPrint genomics, Inc. CONTACT: Richard Gabriel, CEO and President of DNAPrint genomics, +1-941-366-3400; or Ron Stabiner of The Wall Street Group, Inc., +1-212-888-4848, for DNAPrint genomics Web site: http://www.dnaprint.com/ http://www.ancestrybydna.com/

Copyright